Conferences on Antiviral Research present a wealth of new information on novel drug development and the 21st annual meeting, held in Montreal between 13-17 April 2008, was no exception.

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a biopharmaceutical company with a market capitalization ...

Approximately 9.5% (US$15.7 million) of global funding was focused on drug development ... the only factor contributing to the absence of antiviral drugs against dengue, but there can be no ...

The constant need to refill the antiviral drug pipeline to keep up with the emergence ... Antiviral drug development is thus focusing not only on viral targets (e.g., HIV reverse transcriptase ...

The Antiviral Drug Discovery and Development Center (AD3C), coordinated out of the University of Alabama at Birmingham (UAB) has, at its center, the theme to develop new small molecule therapeutics ...

which shows critical gaps in compound discovery and development for mpox and related poxviruses. "Greater transparency from INTREPID's landscape into the antiviral drug pipeline is instrumental in ...

AIM ImmunoTech (AIM) announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company’s ...

Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug ...

"NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases," said Anil R. Diwan, ...